{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T21:03:45Z","timestamp":1760043825263},"reference-count":0,"publisher":"Canadian Science Publishing","issue":"3","license":[{"start":{"date-parts":[[1980,3,1]],"date-time":"1980-03-01T00:00:00Z","timestamp":320716800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.nrcresearchpress.com\/page\/about\/CorporateTextAndDataMining"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Can. J. Physiol. Pharmacol."],"published-print":{"date-parts":[[1980,3,1]]},"abstract":"<jats:p> Soluble polymers of rat (or human) albumin and \u03b1-1,4-glucosidase are prepared using the cross-linking agent glutaraldehyde. The resulting polymer has an average molecular weight of 800\u2002000 indicating an average composition of 12 albumin molecules for each enzyme molecule. Compared with an equivalent amount of free enzyme, the enzyme\u2013albumin polymer has an increased resistance to heat denaturation (half-life of 15\u2002h compared with 1\u2002h for free enzyme at 37 \u00b0C) and to proteolysis by trypsin (half-life of 180\u2002min compared with 10\u2002min). The high degree of resistance to bioinactivation of the enzyme\u2013albumin polymer is discussed in relation to requirements for enzyme replacement therapy in a range of metabolic diseases including type II glycogenosis (Pompe's disease) where \u03b1-1,4-glucosidase is the defective enzyme. <\/jats:p>","DOI":"10.1139\/y80-056","type":"journal-article","created":{"date-parts":[[2011,4,23]],"date-time":"2011-04-23T20:47:30Z","timestamp":1303591650000},"page":"322-325","source":"Crossref","is-referenced-by-count":15,"title":["\u03b1-1,4-Glucosidase\u2013albumin polymers : in vitro properties and advantages for enzyme replacement therapy"],"prefix":"10.1139","volume":"58","author":[{"given":"Mark J.","family":"Poznansky","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Damyanti","family":"Bhardwaj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"155","container-title":["Canadian Journal of Physiology and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nrcresearchpress.com\/doi\/pdf\/10.1139\/y80-056","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,5]],"date-time":"2020-01-05T16:18:45Z","timestamp":1578241125000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.nrcresearchpress.com\/doi\/10.1139\/y80-056"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1980,3,1]]},"references-count":0,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1980,3,1]]}},"alternative-id":["10.1139\/y80-056"],"URL":"https:\/\/doi.org\/10.1139\/y80-056","relation":{},"ISSN":["0008-4212","1205-7541"],"issn-type":[{"value":"0008-4212","type":"print"},{"value":"1205-7541","type":"electronic"}],"subject":[],"published":{"date-parts":[[1980,3,1]]}}}